Lasse Schlör
lasse-schloer@unibo.it

MMM SB & GA meeting
2026-04-20

DC8 / WP3.1: Individually tailored
digital-motor outcomes in real life
Research progress

Funded by the European Union’s Horizon Europe Marie Skłodowska-Curie Actions scheme, GA no. 101120256.

Supervisors

Dr. Sabato Mellone
University of Bologna

Prof. Dr. Matthis Synofzik
University of Tübingen

Prof. Dr. Mats Karlsson
University of Uppsala

Carlo Tacconi
mHealth Technologies s.r.l., Bologna

Prof. Dr. Lorenzo Chiari
University of Bologna

Gait feature extraction summary figure

Gait feature extraction

Context-sensitive analysis

Longitudinal progression modeling

features

Candidate Outcome	ESS
initial_double_support_apdm_d1_μ/mad_compensated/hc_pre_sym/top_svr/median	112
sagittal_maximum_angle_apdm_d1_hann5/mad_compensated/hc_pre_sym/svr/median	132
toe_out_angle_apdm_abs_μ/mad_compensated/hc_pre_sym/top_svr/median	159
sagittal_maximum_angle_apdm/mad_compensated/hc_pre_sym/svr/median	170
cadence_apdm_d2_hann11_μ/mad_compensated/hc_pre_sym/svr/median	191
terminal_swing_apdm_d1_abs_μ/mad_compensated/hc_pre_sym/top_svr/median	193
terminal_swing_apdm_μ/mad_compensated/hc_pre_sym/svr/median	200
sagittal_maximum_angle_apdm_d1_abs/mad_compensated/hc_pre_sym/svr/median	202
initial_plus_mid_swing_apdm_d1_abs_hann5_μ/median_compensated/hc_pre_sym/top_svr/median	210
toe_out_angle_apdm_abs_hann11_μ/mad_compensated/hc_pre_sym/svr/median	231

ESS: Estimated sample size per trial arm to detect 50% progression reduction in a 2-year randomized controlled trial of early-stage
spinocerebellar ataxia with 2 measurements. (Power: 90%, one-sided significance level: 5%.)

Clinical scores

Candidate Outcome	ESS
abc	255
sara	291
abc41	305
sara_pg	381

ESS: Estimated sample size per trial arm to detect 50% progression reduction in a 2-year randomized controlled trial of early-stage
spinocerebellar ataxia with 2 measurements. (Power: 90%, one-sided significance level: 5%.)

Fourier coefficients

Candidate Outcome	ESS
coeff2_abs_dft_acc_y_strides_lumbar_d2_hann11d_μ/mad_compensated/hc_pre_sym/svr/median	93
coeff3_imag_dft_acc_y_strides_lumbar_d2_abs_μ/median_compensated/hc_pre_sym/svr/median	96
coeff3_imag_dft_acc_y_strides_lumbar_d2_abs_hann5_μ/median_compensated/hc_pre_sym/svr/median	96
coeff2_abs_dft_acc_y_strides_lumbar_d1_μ/mad_compensated/hc_pre_sym/top_svr/median	99
coeff2_abs_dft_acc_y_strides_lumbar_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	100
coeff2_abs_dft_acc_y_strides_lumbar_d2_μ/mad_compensated/hc_pre_sym/svr/median	100
coeff2_abs_dft_acc_y_strides_lumbar_d1_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	104
coeff3_imag_dft_acc_y_strides_lumbar_d1_abs_μ/median_compensated/hc_pre_sym/svr/median	115
coeff2_abs_dft_acc_y_strides_lumbar_d2_hann5d_μ/mad_compensated/hc_pre_sym/top_svr/median	115
coeff3_imag_dft_acc_y_strides_lumbar_d1_abs_hann11d_μ/mad_compensated/hc_pre_sym/svr/median	116

ESS: Estimated sample size per trial arm to detect 50% progression reduction in a 2-year randomized controlled trial of early-stage
spinocerebellar ataxia with 2 measurements. (Power: 90%, one-sided significance level: 5%.)

Integrated signal features

Candidate Outcome	ESS
cumulative_gyr_y_strides_abs_d2_abs_μ/median_compensated/hc_pre_sym/svr/median	134
cumulative_acc_y_strides_lumbar_abs_d2_abs_hann11_μ/median_compensated/hc_pre_sym/svr/median	135
cumulative_gyr_y_strides_abs_d2_μ/mad_compensated/hc_pre_sym/svr/median	145
cumulative_gyr_y_strides_abs_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	145
cumulative_gyr_y_strides_abs_d2_abs_hann5_μ/median_compensated/hc_pre_sym/svr/median	146
cumulative_acc_y_strides_lumbar_abs_d2_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	147
cumulative_acc_y_strides_lumbar_abs_d2_μ/mad_compensated/hc_pre_sym/svr/median	150
cumulative_acc_y_strides_lumbar_abs_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	150
cumulative_acc_y_strides_lumbar_d2_abs_hann11_μ/median_compensated/hc_pre_sym/svr/median	152
cumulative_acc_y_strides_lumbar_abs_d1_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	152

ESS: Estimated sample size per trial arm to detect 50% progression reduction in a 2-year randomized controlled trial of early-stage
spinocerebellar ataxia with 2 measurements. (Power: 90%, one-sided significance level: 5%.)

features

Candidate Outcome	ESS
cadence_mobgap_d1_abs_hann5_μ/median_compensated/hc_pre_sym/top_svr/median	119
stride_length_mobgap_normed_d1_abs_hann5d_μ/mad_compensated/hc_pre_sym/top_svr/median	137
stride_length_mobgap_normed_d1_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	159
stride_length_mobgap_d1_abs_hann5_μ/median_compensated/hc_pre_sym/top_svr/median	161
stride_length_mobgap_d1_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	173
stride_length_mobgap_normed_d2_abs_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	196
stride_length_mobgap_normed_d1_abs_hann11d_μ/mad_compensated/hc_pre_sym/svr/median	205
stride_length_mobgap_d2_abs_hann5d_μ/mad_compensated/hc_pre_sym/svr/median	208
cadence_mobgap_d1_abs_hann11d_μ/mad_compensated/hc_pre_sym/svr/median	211
cadence_mobgap_d1_abs_hann5_μ/median_compensated/hc_pre_sym/svr/median	214

ESS: Estimated sample size per trial arm to detect 50% progression reduction in a 2-year randomized controlled trial of early-stage
spinocerebellar ataxia with 2 measurements. (Power: 90%, one-sided significance level: 5%.)

Conclusion

DMOs may outperform clinical scores in early-stage ataxia
Context-aware analysis improves reliability and sensitivity of real-life DMOs

Next up: Reintroduce composite severity scores for further improvement

Proper longitudinal modeling yields realistic ESSs for RCTs
Single-arm N-of-few trials likely require long durations and frequent measurements

Thank you!

Go to index (relative)
Go to index (online)